CytomX CTMX 深 沪
等待开盘 09-26 09:30:00 美东时间
2.70
-0.050
-1.82%
华盛通- 最 高2.78
- 今 开2.74
- 成交量 303.15万股
- 最 低 2.66
- 昨 收 2.75
- 总市值 5.88亿
- 52周最高 8.21
- 市盈率 静 --
- 换手率 1.39%
- 52周最低 2.66
- 委 比 57.93%
- 总股本 2.18亿
- 历史最高 35.00
- 量 比 0.54
- 振 幅 4.36%
- 历史最低 0.40
- 每 手 1
- 风险率 0.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | GoPro获YouTube顶流入股暴升40%；Moderna劲升9.9%，mRNA重磅试验再传捷报；爱迪生国际升近9%
GoPro获YouTube顶流入股暴升40%；Moderna劲升9.9%，mRNA重磅试验再传捷报；爱迪生国际升近9%，监管预期改善推动估值修复>>
09-02 18:51
CytomX gains Fast Track status for colorectal cancer antibody-drug conjugate
The US FDA has granted Fast Track designation to CytomX's (CYTM) antibody-drug conjugate Varseta-M (varsetatug masetecan) for metastatic colorectal cancer. The asset is aimed at epithelial cell adhesi...
08-27 23:34
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
CytomX Therapeutics announced that the FDA has granted Fast Track Designation to Varseta-M for the treatment of relapsed/refractory metastatic colorectal cancer. Varseta-M is a first-in-class antibody drug conjugate targeting EpCAM with a topoisomerase-1 inhibitor payload. The company plans to initiate a potential registrational study for Varseta-M monotherapy in R/R mCRC in the first half of 2027. Fast Track Designation aims to expedite developm...
08-27 12:00
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14
Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $15 to $14.
08-10 22:13
CytomX 2026年第二季度财报：合作收入下降推动亏损扩大
CytomX 2026年第二季度营收141.8万美元，同比下降约92.4%，稀释每股亏损0.09美元，净亏损扩大至2,066.6万美元；季度末现金及投资为3.303亿美元。
08-07 01:38
CytomX 2026年第二季度财报：营收降至141.8万美元，研发投入上升
CytomX 2026年第二季度营收141.8万美元，同比下降92.4%；稀释每股亏损0.09美元，净亏损2066.6万美元。期末现金及投资3.303亿美元，Varseta-M继续推进。
08-06 21:14
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
CytomX Therapeutics, Inc. has appointed Alejandra Carvajal as its new Chief Legal Officer. With over two decades of legal experience in the biotechnology sector, Carvajal will support the company's strategic and operational initiatives. She previously served as Chief Legal Officer at Mersana Therapeutics and Momenta Pharmaceuticals. CytomX, a clinical-stage oncology-focused biopharmaceutical company, is advancing its PROBODY® therapeutic platform...
08-03 12:00
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
CytomX Therapeutics announced it will report second quarter financial results on August 6, 2026, followed by a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants can access the webcast via the company’s website or register for the call in advance. The company, focused on developing conditionally activated biologics for cancer treatment, highlights its pipeline including varsetatug masetecan (Varseta-M) and CX-801. CytomX col...
07-30 12:00
Rigel appoints Alison L. Hannah as chief medical officer
Rigel Pharmaceuticals (RIGL) announced on Wednesday the appointment of Alison L. Hannah, M.D., to the role of executive vice president and chief medical officer. The company noted that Hannah has res...
07-01 20:58
